NASDAQ$IART
Integra LifeSciences Holdings Corporation · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported an increase in revenue and adjusted earnings per diluted share remained flat compared to the fourth quarter of 2020.
Integra LifeSciences reported a revenue increase of 4.3% on a reported basis and 8.3% on an organic basis for Q4 2021. GAAP earnings per diluted share were $0.53, while adjusted earnings per diluted share were $0.84, flat compared to Q4 2020.
- Reported revenues increased by 4.3% on a reported basis and 8.3% on an organic basis compared to Q4 2020.
- GAAP earnings per diluted share were $0.53, compared to $1.09 in Q4 2020.
- Adjusted earnings per diluted share were $0.84, flat compared to Q4 2020.
- Adjusted EBITDA for Q4 2021 was $105.4 million, compared to $102.7 million in Q4 2020.
Headline financials
Revenue & EPS history
Integra LifeSciences · Revenue · Quarterly
$406M
Revenue by segment
Integra LifeSciences · $360M total across 4 segments · Q1 2021
- Neurosurgery$189M+2.3%52.6%
- Wound Reconstruction and Care$88.7M+22.7%24.6%
- Instruments$52M+11.8%14.4%
- Private Label$30.1M+3.4%8.4%
Forward guidance
The Company’s guidance for 2022 revenue and adjusted earnings per share reflects the continuing uncertainty around the scope and duration of the pandemic, and its related impacts on our business in the first half of the year.
Tailwinds
- Full-year 2022 revenue is expected to be in the range of $1,580 million to $1,600 million, representing reported growth of approximately 2.5% to 3.5%.
- Full-year 2022 organic growth is expected to be approximately 3.5% to 5%.
- Adjusted earnings per diluted share are expected to be in a range of $3.27 to $3.35 for full-year 2022.
- The company entered into an accelerated share repurchase agreement with Citibank, N.A. to repurchase $125 million in the aggregate.
- The repurchase transactions are expected to be completed in the first half of 2022.
Headwinds
- First quarter 2022 reported revenues are expected to be in the range of $357 million to $365 million, representing reported growth of approximately -1% to 1.5%.
- First quarter 2022 organic growth is expected to be approximately 0% to 2.5%.
- Adjusted earnings per diluted share are expected to be in a range of $0.67 to $0.71 for the first quarter 2022.
- The guidance reflects the continuing uncertainty around the scope and duration of the pandemic.
- The guidance reflects the related impacts on our business in the first half of the year.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
-0.2%
Avg return
Earnings day
-1.4%
Avg return
5 days after
-1.8%
Avg return
30 days after
51%
35 / 68 earnings
Positive
+29.2%
Q3 2024
Best reaction
-23.5%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +24.4% | +31.0% | +65.1% | |
| Q4 2025 | -2.1% | -8.9% | -20.6% | |
| Q3 2025 | -23.5% | -26.8% | -15.0% | |
| Q1 2025 | -20.9% | -27.3% | -22.3% | |
| Q4 2024 | +12.1% | +5.3% | -0.2% | |
| Q3 2024 | +29.2% | +28.5% | +25.1% | |
| Q2 2024 | -20.4% | -23.5% | -35.3% | |
| Q1 2024 | -13.2% | -10.0% | +9.9% | |
| Q4 2023 | -16.6% | -18.8% | -19.9% | |
| Q3 2023 | -4.5% | -5.8% | +6.3% | |
| Q2 2023 | -3.1% | -1.1% | -9.5% | |
| Q1 2023 | -6.2% | -5.5% | -34.7% | |
| Q4 2022 | +0.2% | +0.8% | -3.1% | |
| Q3 2022 | +11.1% | +12.7% | +21.1% | |
| Q2 2022 | -1.5% | -0.5% | -14.8% | |
| Q1 2022 | +2.9% | -0.2% | +2.5% | |
| Q4 2021 | +0.9% | +2.6% | -2.8% | |
| Q3 2021 | +7.1% | +7.5% | -5.3% | |
| Q2 2021 | -0.2% | -0.3% | +2.6% | |
| Q1 2021 | -2.0% | -3.4% | -9.9% | |
| Q4 2020 | -4.1% | -2.8% | -6.2% | |
| Q3 2020 | -7.0% | -4.5% | +19.5% | |
| Q2 2020 | +6.4% | +6.6% | -5.6% | |
| Q1 2020 | +1.5% | -2.8% | +7.9% | |
| Q4 2019 | +2.9% | -0.3% | -35.7% | |
| Q3 2019 | -7.7% | -5.1% | -2.0% | |
| Q2 2019 | +12.0% | +14.5% | +8.0% | |
| Q1 2019 | -3.1% | -2.3% | -7.7% | |
| Q4 2018 | +5.7% | +6.1% | +6.5% | |
| Q3 2018 | -12.6% | -13.5% | -13.9% | |
| Q2 2018 | -2.3% | -2.3% | -5.5% | |
| Q1 2018 | +9.8% | +12.7% | +16.7% | |
| Q4 2017 | -4.1% | -4.1% | +0.7% | |
| Q3 2017 | -9.1% | -8.2% | -4.9% | |
| Q2 2017 | -9.9% | -10.7% | -10.9% | |
| Q1 2017 | +4.6% | +5.1% | +12.1% | |
| Q4 2016 | -2.1% | -1.2% | -1.2% | |
| Q3 2016 | +1.6% | -3.4% | +3.8% | |
| Q2 2016 | +6.8% | +6.4% | +9.0% | |
| Q1 2016 | +6.7% | — | — | |
| Q4 2015 | +3.8% | — | — | |
| Q3 2015 | +2.8% | — | — | |
| Q2 2015 | -0.1% | — | — | |
| Q1 2015 | +7.5% | — | — | |
| Q4 2014 | +2.3% | — | — | |
| Q3 2014 | -7.5% | — | — | |
| Q2 2014 | +1.0% | — | — | |
| Q1 2014 | -1.6% | — | — | |
| Q4 2013 | -3.9% | — | — | |
| Q3 2013 | +4.4% | — | — | |
| Q2 2013 | -2.2% | — | — | |
| Q1 2013 | +0.2% | — | — | |
| Q4 2012 | -4.8% | — | — | |
| Q3 2012 | -0.3% | — | — | |
| Q2 2012 | +4.1% | — | — | |
| Q1 2012 | +9.4% | — | — | |
| Q4 2011 | +1.2% | — | — | |
| Q3 2011 | -21.8% | — | — | |
| Q2 2011 | -5.3% | — | — | |
| Q1 2010 | +2.1% | — | — | |
| Q1 2011 | +0.8% | — | — | |
| Q4 2008 | -0.7% | — | — | |
| Q4 2010 | -0.7% | — | — | |
| Q3 2010 | +2.2% | — | — | |
| Q3 2009 | +2.2% | — | — | |
| Q2 2009 | +6.2% | — | — | |
| Q2 2010 | +6.2% | — | — | |
| Q4 2009 | +6.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro